Oppenheimer Raises Target on ViroPharma (VPHM) Following Q4 Results

Oppenheimer lifted its price target on Outperform-rated ViroPharma (NASDAQ: VPHM) from $32 to $34 following GAAP EPS of $0.65, above their $0.41 estimate owing to lower expenses and taxes as well as a lower than expected share count.

The firm highlighted total Cinryze revenues of $66.7M were below their $71.3M estimate while Vancocin revenues of $78.7M were ahead of their $69.9M estimate. Average dose per patient has remained stable at 1.75 doses

"We expect VPHM to complete the FDA's requests and anticipate manufacturing approval by late 3Q12. We highlight enrollment for SC Cinryze dose-ranging study will be complete by YE12."

For an analyst ratings summary and ratings history on ViroPharma click here. For more ratings news on ViroPharma click here.

Shares of ViroPharma closed at $32.24 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Aebi Schmidt Holding AG (AEBI) PT Raised to $17 at DA Davidson Following Q2 Results
• Harley-Davidson (HOG) PT Raised to $33 at DA Davidson Amid Progress on Back to Bricks Strategy
• Target (TGT) PT Raised to $170 at DA Davidson Ahead of Q2 Earnings